PharmaTech

JUNE 26, 2025

million) in non-dilutive funding through i-Nov, an innovation competition and flagship French government program that is part of the France 2030 initiative, operated by Bpifrance (1). million (approximately US$1.99 The company said in June 2025 that it raised €11.25 million (US$12.9

Dosage 59

Dosage Drug Development Vaccines Labelling 59

Pharmacy Times

JUNE 12, 2025

4,5 In most cases, HPV infections are short-lived and resolve on their own within 1 to 2 years, as the immune system clears the virus. 5 The vaccine is most effective when given in pre-teen or early teen years when the immune system is most responsive. 5 "There are 3 products on the market,” said Castle.

Vaccines 26

Vaccines Pharmacy Technician Immunization Immunity 26

Pharmaceutical Technology

JULY 8, 2025

Go deeper with GlobalData Reports LOA and PTSR Model - Briquilimab in Severe Combined Immune Deficien. Reports LOA and PTSR Model - Immune Globulin (Human) in Chronic Lymphocytic. Reports LOA and PTSR Model - Immune Globulin (Human) in Chronic Lymphocytic. Data Insights The gold standard of business intelligence.

Immunization 52

Immunization Immunity Packaging Hospitals 52

Pharmaceutical Technology

JULY 14, 2025

A single dose of the vaccine in adults aged 18-49 at increased risk of RSV-LRTD elicited robust immune responses that were non-inferior to those observed in adults aged 60 and above. The global RSV market is set to reach $6.3bn in value by 2030, according to analysis by GlobalData.

Labelling 52

Labelling Vaccines Insurance Coverage and Processing Packaging 52

European Pharmaceutical Review

JUNE 6, 2025

billion by 2030, driven by the rising demand for off-the-shelf therapies that offer scalable, standardised solutions for treating a wide range of diseases, including cancer and auto-immune diseases. Cancer Immunity and Immunotherapy. The global cell therapy market is projected to reach $20.07 Internet] Grand View Research.

Immunization 52

Immunization Immunity 52

Express Pharma

MARCH 29, 2023

Working with partners including the World Food Program, UNICEF and Sight and Life, DSM will extend its impact as it targets helping to close the micronutrient gap of 800 million people by 2030. The company aims to support 500 million people by 2030. per cent); phosphorus eutrophication from poultry farming (by 6.8 per cent).

Immunization 96

Immunization Immunity 96

Express Pharma

OCTOBER 16, 2024

Ophelia Chan, Business Fundamentals Senior Analyst at GlobalData, comments, “The COVID-19 pandemic highlighted the key advantages of mRNA technology in vaccine development, including rapid production, precise immune targeting, and streamlined manufacturing- factors that drove the success of mRNA-based COVID-19 vaccines.” billion in 2030.

Vaccines 105

Vaccines Immunization Immunity Diabetes 105

European Pharmaceutical Review

NOVEMBER 18, 2022

Achieving Immunization Agenda 2030 goals. The report highlighted opportunities for more alignment of vaccine development, production and distribution with a public health agenda, towards achieving the Immunization Agenda 2030 (IA2030) goals and informing pandemic prevention, preparedness and response efforts.

Vaccines 98

Vaccines Immunization Immunity Documentation 98

European Pharmaceutical Review

JULY 12, 2023

They do not promote herd immunity and are not generally effective in infants and children younger than two years old. Therefore, having access to this vaccine will “move us closer to defeating meningitis by 2030″ noted the UK’s International Development Minister Andrew Mitchell. However, they only provide short-term protection.

Vaccines 98

Vaccines Immunization Immunity 98

European Pharmaceutical Review

DECEMBER 2, 2022

Vaccines Europe states that the actions must be addressed to ensure the European Beating Cancer Plan and the Immunization Agenda 2030 are met. The organisation claims it is crucial to account for vaccine specificities when shaping Europe’s research ecosystem, through revision of the General Pharmaceutical Legislation.

Vaccines 98

Vaccines Immunization Immunity 98

pharmaphorum

JANUARY 19, 2023

Alopecia areata is an autoimmune disease in which the immune system attacks the body’s hair follicles, causing hair to fall out, predominantly on the scalp, but also sometimes affecting other areas of the body like eyebrows, eyelashes, and facial hair. .” The $11.50

Labelling 98

Labelling Immunization Immunity 98

pharmaphorum

JUNE 8, 2021

The entire APAC region already accounts for 30% of all global pharma spending, and within these markets national healthcare expenditure is expected to increase threefold to over $2 trillion by 2030. million in 2030. New cancer cases in China increased from 4 million in 2015 to 4.4 million in 2019, and are estimated to increase to 5.7

Chemotherapy 105

Chemotherapy Pharmaceutical Companies Pharmaceutical Companies Immunization 105

Express Pharma

MARCH 20, 2023

India is preparing to include human papillomavirus (HPV) vaccines as part of the government-driven public immunization program popularly known as the Universal Immunization Program (UIP). million in 2030. The Indian government will float a global tender in April 2023 to procure HPV vaccines. per cent from 0.43

Vaccines 52

Vaccines Immunization Immunity 52

pharmaphorum

JULY 28, 2021

Under the agreement, Calico is responsible for research and early development until 2025 and will take projects through phase 2a trials until 2030, with AbbVie having an option to take over projects once they reach later-stage development and lead commercialisation efforts.

Immunization 59

Immunization Immunity Drug Development 59

pharmaphorum

MARCH 10, 2022

Biologics product development has increased steadily over the past decade, with the volume of business forecast to double by 2030. Driven by advancements in technology, these complex therapeutics have already made waves in life sciences, providing revolutionary treatment options in oncology, immune conditions and rare diseases.

Pharmaceutical Companies 98

Pharmaceutical Companies Pharmaceutical Companies Packaging Immunization 98

Express Pharma

MAY 22, 2023

As the world grappled with the COVID-19 pandemic, and now continues to deal with its aftermath, ‘immunity’ has become the new buzzword and the demand for nutraceuticals across the globe has increased manifold. Read: [link] www.expresspharma.in/six-reasons-why-india-is-poised-to-be-aglobal-leader-in-nutraceuticals/

Dosage 106

Dosage Method Validation Labelling Immunization 106

PharmaShots

MARCH 13, 2023

IgA immune complexes are higher in circulation when patients have respiratory infections such as a cough or sore throat, therefore, many of them end up depositing in the kidneys and this is when patients with IgA nephropathy typically present with symptoms such as hematuria (blood in the urine).

Mayo Clinic 40

Mayo Clinic Immunization Immunity 40

European Pharmaceutical Review

MARCH 7, 2024

Firstly, alpha particles exhibit greater biological effectiveness by inducing irreparable DNA double-strand breaks, minimising the risk of resistance or immune escape in tumour cells. However, by employing alpha particles, TAT offers two crucial advantages.

Pharmaceutical Companies 52

Pharmaceutical Companies Pharmaceutical Companies Immunization Immunity 52

PharmaShots

JUNE 29, 2023

A portmanteau of nutrients and pharmaceuticals, nutraceuticals are colloquially known as medical foods With a market size of $413B in 2021, the nutraceutical market value is forecasted to cross the threshold of $650B by 2030 by marking a remarkable CAGR of 3.9 percent from 2021 to 2030.

Immunization 40

Immunization Immunity 40

Pharmaceutical Technology

MAY 25, 2023

The results from a trial, published in The New England Journal of Medicine , found the vaccine was associated with a strong immune response and good safety profile. The World Health Organization (WHO) has set a goal of ending the meningitis epidemic by 2030.

Vaccines 78

Vaccines Immunization Immunity 78

PharmaShots

APRIL 11, 2023

by 2030 at a CAGR of 6.9% Market Size:4 The global hemophilia market size accounted for $12.2B in 2021 and is projected to increase at $22.2B

Immunization 64

Immunization Immunity Vaccines 64

pharmaphorum

JUNE 1, 2022

According to the World Health Organization, the world will need more than 40 million new doctors, nurses, frontline healthcare workers, and various other healthcare professionals by 2030. This equates to approximately doubling the current medical workforce.

Vaccines 145

Vaccines Immunization Immunity Hospitals 145

Pharmacy Friday Pearls

MARCH 9, 2022

Crotalidae Polyvalent Immune FAB (Ovine). Crotalidae Immune F(ab’)2 (Equine). 2001;161(16):2030-6. Patients can develop delayed or recurrent hematologic symptoms up to a week after treatment cessation, especially following a severe envenomation. Pharmacology. Cocchio C, et al Am J Health Syst Pharm. 2020;77(3):175-187.

Immunization 40

Immunization Immunity Packaging Labelling 40

pharmaphorum

JANUARY 10, 2023

Since then, the two partners have developed multiple AI-based applications including a platform for selecting neoantigens for use in individualised cancer vaccines and an early warning system for high risk SARS-CoV-2 variants based on how well they can evade the immune system and their transmissibility.

Immunization 116

Immunization Immunity Vaccines 116

European Pharmaceutical Review

SEPTEMBER 1, 2023

billion by 2030 BioNTech Development of mRNA-based oncology therapies for German biotech BioNTech is progressing. During the American Society of Clinical Oncology (ASCO) 2023 annual meeting, BioNTech revealed promising Phase I results for the pancreatic cancer drug BNT122 combined with the immune checkpoint inhibitor (ICI) atezolizumab.

Immunization 110

Immunization Immunity Vaccines 110

pharmaphorum

JANUARY 6, 2023

The cancer immunotherapies will mainly be provided in the context of clinical trials over the alliance, which extends out to 2030, but also covers supply of commercial therapies if approved in the interim. It will also cover some infectious disease targets.

Vaccines 111

Vaccines Immunization Immunity Drug Development 111

PharmaTech

JUNE 10, 2025

The global biopharma industry is expected to increase at a compound annual growth rate of 8.97% from 2025 to 2030; this growth is suspected to result from a demand for targeted therapies, new alliances, and increased innovation (1).

Dosage 52

Dosage Drug Development Vaccines Compounding 52

Pharmaceutical Technology

FEBRUARY 24, 2023

The WHO’s 2020 global strategy sets out its vision of cervical cancer being eliminated as a public health problem by 2030 and outlines a pathway with strategic actions to achieve its goal.

Vaccines 116

Vaccines Communication Medical Schools Immunization 116

Pharmacy Times

NOVEMBER 4, 2022

WHO has released a global plan for hepatitis B elimination by 2030, including goals to increase pediatric and maternal immunization and to improve screening and treatment.

Vaccines 26

Vaccines Immunity Immunization 26

European Pharmaceutical Review

JUNE 27, 2022

The Kigali Summit on Malaria and NTDs , hosted by His Excellency (HE) Paul Kagame, President of the Republic of Rwanda, on Thursday 23 June 2022, gathered world leaders to commit to ending these devastating diseases by the end of 2030. Did you know, 1.7

Vaccines 110

Vaccines Communication Documentation Compounding 110

pharmaphorum

SEPTEMBER 16, 2022

Despite the RSV vaccine threat, analysts at GlobalData have predicted that nirsevimab could reach $3 billion in annual revenue by 2030, assuming a launch next year. Both vaccines are also being tested in older adults. In part, that is because of the scale of the public health crisis caused by RSV. Photo by Christian Bowen on Unsplash.

Vaccines 59

Vaccines Immunization Immunity 59

Express Pharma

MAY 2, 2025

billion in 2030. billion by 2030, accounting for 80.11 KOLs noted that the key hurdles are associated with the administration of gene therapies, which pose a challenge to treatment delivery, such as immune responses to vectors or gene products, as well as mutagenicity. CAGR through 2030 appeared first on Express Pharma.

Compounding 66

Compounding Immunization Immunity 66

Express Pharma

JANUARY 15, 2025

per cent expected from 2025 to 2030, the event will serve as a hub for Distributors, Procurement Managers, Product Development Experts, Regulatory Affairs Professionals, and R&D specialists. per cent and a forecasted value of USD 12 billion by 2030. In India, a nation of 1.4

Labelling 106

Labelling Immunization Immunity Compounding 106

Pharmaceutical Business Review

DECEMBER 26, 2024

This also stands as a commitment from our side to support the 2030 vision ofSaudi Arabiathrough localising biopharmaceutical products in the Kingdom.” This mechanism is crucial in controlling inflammatory and immune responses.

Biosimilars 52

Biosimilars Immunization Immunity Pharmaceutical Companies 52